纤溶酶原

阿罗洛尔对不稳定型心绞痛患者高敏C反应蛋白和纤溶酶原激活物抑制剂-1含量的影响

Effect of Arotinolol on High-sensitive C-reactive Protein and Plasminogen Activator Inhibitor-1 in Patients with Unstable Angina

组织型纤溶酶原激活物基因的DNA改组

DNA family shuffling of tissue-type plasminogen activator genes

血清胆固醇水平与血浆纤维蛋白原水平和纤溶酶原激活物抑制剂-1活性呈显著的正相关性（P＜0.05）。

Serum cholesterol level was also positively correlated with plasma fibrinogen level and PAI-1 activity ( P0.05 ) .

RT-PCR检测胃癌组织中尿激酶型纤溶酶原激活剂mRNA水平表达

Expression of Urokinase-type Plasminogen Activator mRNA in Gastric Cancer Tissues

葛根素对不稳定心绞痛患者血小板颗粒膜蛋白、溶酶体膜蛋白及血浆纤溶酶原激活物抑制物、C反应蛋白的影响

Effect of Puerarin on Platelet Activating Factors CD63 and CD62P , Plasminogen Activator Inhibitor and C-reactive Protein in Patients with Unstable Angina Pectoris

目的：探讨C反应蛋白对内皮细胞株304细胞释放前列环素、纤溶酶原激活物抑制剂1的影响。

AIM : To investigate the effect of C reactive protein on prostaglandin and plasminogen activator inhibitor-1 in endothelial cell strain 304 cells .

关节盘前移位对关节滑膜尿激酶型纤溶酶原激活剂及其1型抑制剂mRNA表达的影响

Effect of Disc Displacement on mRNA Expression of Urokinase Plasminogen Activator and Its Inhibitor - 1 in Synovial Tissues

IgA肾病患者纤溶酶原激活物的变化及临床意义

The changes of plasminogen activators in patients with IgA nephropathy and their clinical significance

EGF对小鼠角质形成细胞中组织型纤溶酶原激活剂表达的调节

Regulation of tissue plasminogen activator expression by EGF in epidermal keratinocytes of mouse

目的：了解5／6肾切除大鼠尿纤溶酶原激活物（PA）排泄量的动态变化。

Objective : to observe the urinary plasminogen activator ( PA ) excretion in5 / 6 nephrectomized rats .

方法：采用纤维蛋白原平板溶环法，检测尿中纤溶酶原激活物PA的活性；

Method : Fibrin plate method was applied to examine activity of urinary plasminogen activator ( PA ) .

MCF-7细胞中组织型纤溶酶原激活剂乳腺特异性表达载体的瞬时表达

Transient expression of tissue-type plasminogen activator in mammary carcinoma cell line MCF-7

Ⅰ型纤溶酶原激活物抑制物在IgA肾病肾小管间质损伤中的作用研究

Role of type I plasminogen activator inhibitor in mediating renal tubulointerstitial injury of patients with IgA nephropathy

组织型纤溶酶原激活剂（t-PA）及其突变体的表达研究进展

Progresses in the Expression of Tissue-Type Plasminogen Activator and Its Mutants

可溶性尿激酶型纤溶酶原激活物受体在RA患者血浆和滑液的水平及其临床意义

Detection and significance of soluble urokinase-type plasminogen activator receptor in plasma and synovial fluid of patients with rheumatoid arthritis

野生型组织型纤溶酶原激活剂（t-PA）工程细胞株生物学特性分析

The analysis of biological characteristics for the wild-type t-PA engineering cell lines

组织型纤溶酶原激活剂（t-PA）、纤溶酶原激活剂抑制剂（PAI）均是体内纤溶系统的重要组成部分。

PAI and t-PA are important constituents of fibrinolytic system in human body .

酶谱分析法检测其纤溶酶原激活物（tPA）活性。

Zymography analysis for determining the activity of tissue type plasminogen activators ( tPA ) .

尿激酶型纤溶酶原激活剂（uPA）系统在子宫内膜癌中的研究进展

Study On uPA System in the Carcinoma of Endometrium

SQ复方能降低纤溶酶原激活物（t-PA）的含量。

SQ complex prescription decreased the contends of tissue plasminogenactivator ( t-PA ) .

抗PAI抑制作用的组织纤溶酶原激活剂在大肠杆菌中的表达

Expression and activity of tissue-type plasminogen activator mutant reteplase with deletion of PAI-1 binding sites

NIDDM病人血浆组织型纤溶酶原激活物及其抑制物的活性水平与胰岛素抵抗关系的探讨

The Relationship of Tissue Plasminogen Activator and Inhibitor Activity Levels with Insulin Resistance in NIDDM Patient

肝X受体激动剂对高脂载脂蛋白E基因缺陷小鼠动脉壁一氧化氮合酶、增殖细胞核抗原和纤溶酶原激活物抑制剂1表达的影响

The Effects of Liver X Receptor Agonists on the Expressions of Nitric Oxide Synthase , Proliferating Cell Nuclear Antigen and Plasminogen Activator Inhibitor-1 in the Artery of Apolipoprotein E-Deficient Mice

组织型纤溶酶原激活剂（t-PA）对实验性青光眼滤过性手术瘢痕形成的影响

Effects of tissue plasminogen activator ( t-PA ) on scar formation after experimental filtration surgery

尿激酶型纤溶酶原uPA和P~（27）蛋白在乳腺癌中的表达及其意义

Expression and clinical significance of uPA and P ~ ( 27 ) protein in breast cancer

本文建立了组织型纤溶酶原激活剂（t-PA）活力的发光固相测定方法。

A luminescence solid phase assay for tissue type plasminogen activator ( t-PA ) was developed .

单链尿激酶型纤溶酶原激活剂Kringle结构域催化功能探讨

Catalysis-related Function of Kringle Domain of Single Chain Urokinase-type Plasminogen Activator

实验性颈动脉粥样硬化模型中血栓素B2和6-酮-前列腺素F1α与抗凝血酶Ⅲ和纤溶酶原活性的改变

The Changes of Thromboxane B2 , 6-ket-prostaglandin F1 α, Antithrombin ⅲ and Plasminogen in a Experimental Carotid Atherosclerotic Model of Rabbits

本研究报道动脉硬化性脑梗塞患者和TIA患者血浆组织型纤溶酶原激活物（t&PA）含量、活性及其抑制物（PAI）活性在缺血性脑卒中发病后一段时间内的动态变化。

T-PA content 、 activity and its inhibitor PAI were dynamically measured in two groups of patients with ischemic stroke .

发色底物法检测内皮细胞培养液中的组织纤溶酶原激活物（t-PA）和纤溶酶原激活物抑制剂（PAI-1）的活性；

Tissue plasminogen activator ( t-PA ) and plasminogen activator inhibitor-1 ( PAI-1 ) activity were measured with chromogenix ;